Real-World Evidence for a Smartwatch-based Parkinson’s Motor Assessment App in Patients Undergoing Therapy Changes
Objective: We sought to investigate patient and clinician usability of a smartwatch-based wearable motor assessment system for measuring Parkinson’s disease (PD) motor symptoms in patients undergoing…CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks
Objective: A post hoc analysis of UPDRS-III sequential changes over the 12-week treatment period of a phase 3 study. Background: CVT-301 is an inhaled levodopa…Instrumented Detection of Fluctuations with Wearable Devices in Parkinson’s Disease
Objective: The objective of this study is to evaluate the efficacy in fluctuations detection of a system consisting of wearable devices embedding Inertial Measurement Units…Among Parkinson’s disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials
Objective: Evaluate the effects of ADS-5102 (amantadine) extended release capsules on motor complications and functional outcomes among patients experiencing both troublesome dyskinesia and OFF (disruptive…Use in Clinical Practice of a Personalised and Long-term Monitoring Device for Parkinson´s Disease: STAT-ON
Objective: To analyze the opinion of different neurologists from Spain about the STAT-ON tool after using the device in a real clinical practice setting (RCPS).…Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study
Objective: Evaluate the efficacy of apomorphine (APO) infusion in reducing OFF time during the hours of pump use in PD patients with motor fluctuations inadequately…Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…Levodopa and dopamine agonists dosage changes after Opicapone introduction
Objective: We aim to analyze changes in levodopa and dopamine agonists (DA) dosage after introduction of opicapone (OPC) in a daily clinical practice setting. Background:…Motor subtype change between OFF and ON periods in patients with Parkinson’s disease
Objective: To identify if there is any difference in the motor subtype of PwPD between "off" stage and "on" stage. Background: Patients with Parkinson’s disease…Efficacy and tolerability of opicapone in Parkinson´s disease in usual clinical practice
Objective: To evaluate the efficacy and tolerability of opicapone in usual clinical practice in patients with Parkinson's disease (PD). Background: Opicapone is a recently approved…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 26
- Next Page »